Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Pharmacological Studies on Drug-Drug Interactions between Antidiabetic Drug (Glibenclamide) and Selective Anti-HIV Drug (Lamivudine) in Rats and Rabbits


Affiliations
1 Dept. of Pharmacology, HKES MTRIPS, Kalaburagi, Karnataka -585105, India
     

   Subscribe/Renew Journal


The studies were conducted in normal and diabetic rats, and in normal rabbits to find out the influence of lamivudine on pharmacodynamics of glibenclamide. Rats were divided into four groups each containing six. Group-I: treated with therapeutic dose (TD) of lamivudine (5.4mg/200g body weight). Group-II: treated with therapeutic dose of glibenclamide (0.18mg/200g body weight). Group-III: treated with combination of therapeutic dose of lamivudine and glibenclamide. Group-IV: served as control (acacia suspension l% w/v). Same grouping was done for multiple days of therapeutic dose (MTD) studies (10 days), double therapeutic dose (2TD) and multiple days of double therapeutic dose (M2TD) studies (10 days). Streptozotocin at a dose of 50mg/kg body weight intraperitoneally was used to induce diabetes. Rats with glucose levels more than 200mg/dL were considered as diabetic. The experiment was carried out as described for normal rats. The influence of combination of both the drugs was studied in normal rabbits. A group of normal rabbits were taken and the experiment was carried out as described for normal rats. The results indicate that lamivudine produced significant increase in blood glucose, thereby it alters the hypoglycaemic activity of glibenclamide in normal rats, diabetic rats as well as in normal rabbits. As the interaction has been found in two dissimilar species that is rats and rabbits it indicates, it may occur in humans also.

Keywords

Lamivudine, Interaction, Anti-HIV, Diabetes, Anti-Diabetic, Blood Glucose Level.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Steel, K.K., Gertman, P.M., Cresienze, C., Andersen J. Latrogenic illness on a general medical service at a university hospital. N Eng J Med 1981; 34, 638-642.
  • Pirmohammed, M., James, S., Meakin, S., Green C., Scott, A.K., Walley, T.J., Adverse drug reaction as cause of admission to hospital: Prospective Analysis of 18820 Patients.; BMJ 2004; 329, 15-19.
  • Arky R.A. clinical correlates of metabolic derangement of Diabetes Mellitus. In complications of diabetes mellitus. W.B. Saunders, Philadelphia, 1982; 16-20.
  • Zimmet, P.Z., Diabetes epidemiology as a tool to trigger diabetes research and care. Diabetologia 1991; 42, 499-518.
  • Bach, J. F. Insulin dependent diabetes mellitus as β-cell targeted disease of immunoregulation. J. Autoimmunol 1995; 8, 439-463.
  • Athena Philis-Tsimikas, Guillaume Charpentier, Per Clauson, Gabriela Martinez Ravn, Victor Lawrence Roberts and Birger Thorsteinsson. Comparison of Once Daily Insulin Detemir with NPH Insulin Added to a Regimen of Oral Antidiabetic Drugs in poorly controlled Type 2 Diabetes. Clinical therapeutics 2006; 28, 1569-1581.
  • Goodman and Gilman. The pharmacological Basis of Therapeutics. 10th ed. New York: McGraw Hills, Medical Publication; 2008.
  • Venkateswaran S, Pari L. Effect of Coccinia indica leaves on antioxidant status in streptozotocin-induced diabetic rats. J Ethnopharmacol 2003; 163-168.

Abstract Views: 192

PDF Views: 0




  • Pharmacological Studies on Drug-Drug Interactions between Antidiabetic Drug (Glibenclamide) and Selective Anti-HIV Drug (Lamivudine) in Rats and Rabbits

Abstract Views: 192  |  PDF Views: 0

Authors

Bhavimani Guru
Dept. of Pharmacology, HKES MTRIPS, Kalaburagi, Karnataka -585105, India
M. Nitin
Dept. of Pharmacology, HKES MTRIPS, Kalaburagi, Karnataka -585105, India

Abstract


The studies were conducted in normal and diabetic rats, and in normal rabbits to find out the influence of lamivudine on pharmacodynamics of glibenclamide. Rats were divided into four groups each containing six. Group-I: treated with therapeutic dose (TD) of lamivudine (5.4mg/200g body weight). Group-II: treated with therapeutic dose of glibenclamide (0.18mg/200g body weight). Group-III: treated with combination of therapeutic dose of lamivudine and glibenclamide. Group-IV: served as control (acacia suspension l% w/v). Same grouping was done for multiple days of therapeutic dose (MTD) studies (10 days), double therapeutic dose (2TD) and multiple days of double therapeutic dose (M2TD) studies (10 days). Streptozotocin at a dose of 50mg/kg body weight intraperitoneally was used to induce diabetes. Rats with glucose levels more than 200mg/dL were considered as diabetic. The experiment was carried out as described for normal rats. The influence of combination of both the drugs was studied in normal rabbits. A group of normal rabbits were taken and the experiment was carried out as described for normal rats. The results indicate that lamivudine produced significant increase in blood glucose, thereby it alters the hypoglycaemic activity of glibenclamide in normal rats, diabetic rats as well as in normal rabbits. As the interaction has been found in two dissimilar species that is rats and rabbits it indicates, it may occur in humans also.

Keywords


Lamivudine, Interaction, Anti-HIV, Diabetes, Anti-Diabetic, Blood Glucose Level.

References